Even if Amarin prevails in its patent infringement lawsuit, its key patents on Vascepa are likely to be ruled invalid in ongoing litigation, opening the way for generic formulations.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Curfman, G. JAMA Intern. Med. 177, 194 (2017).
Manson, J. E. et al. N. Engl. J. Med. 380, 23–32 (2019).
Ballantyne, C. M. et al. Am. J. Cardiol. 110, 984–992 (2012).
Bays, H. E. et al. Am. J. Cardiol. 108, 682–690 (2011).
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc. 033020 NVDC, 2:16-cv-02525-MMD-NJK.
Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc. et al. USCAFC 20-1723, doc 70, 9-30-2020.
US Food and Drug Administration. ANDA approval letter to Hikma Pharmaceuticals USA Inc. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209457Orig1s000ltr.pdf, (2020).
Bhatt, D. L. et al. N. Engl. J. Med. 380, 11–22 (2019).
US Food and Drug Administration. Supplement approval letter to Amarin Pharma Inc. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/202057Orig1s035ltr.pdf, (2019).
Federal Food, Drug, and Cosmetic Act, Section 505(j)(2)(A)(viii).
US Food and Drug Administration. Preface, Orange Book, 42nd edn, https://www.fda.gov/drugs/development-approval-process-drugs/orange-book-preface, (2022).
Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc et al. C.A. No. 20-1630-RGA-JLH; https://www.ded.uscourts.gov/sites/ded/files/opinions/20-1630.pdf (August 2021).
Amarin Pharma v. Hikma Pharm. US. C.A. 20-1630-RGA-JLH (D. Del., https://casetext.com/case/amarin-pharma-v-hikma-pharmus, (January 2022).
Silbersher, Z. Will Amarin’s new cardiovascular patent lawsuit against Hikma keep out generic sales? Markman Advisors, https://www.markmanadvisors.com/blog/2020/12/2/will-amarins-new-cardiovascular-patent-lawsuit-against-hikma-keep-out-generic-sales (December 2020).
Yokoyama, M. et al. Lancet 369, 1090–1098 (2007).
Nicholls, S. J. et al. J. Am. Med. Assoc. 324, 2268–2280 (2020).
Gugliuzza, P. R. Iowa Law Rev. 106, 607–664 (2021).
35 USC § 103; https://www.law.cornell.edu/uscode/text/35/103
Graham v. John Deere Co. 383 US 1, 148 USPQ 459 (1966).
KSR International Co. v. Teleflex Inc. 550 US 398, 82 USPQ2d 1385 (2007).
The authors declare no competing interests.
About this article
Cite this article
Curfman, G., Cole, J. Vascepa patents under legal scrutiny. Nat Biotechnol 40, 829–831 (2022). https://doi.org/10.1038/s41587-022-01345-8